diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM10227diaendo-10227Research ArticleНовостиNewsРезолюция по итогам первой рабочей встречи научно-консультативного совета по вопросу «Актуальные проблемы вариабельности гликемии как нового критерия гликемического контроля и безопасности терапии сахарного диабета»Resolution on the results of the first working meeting of the scientific advisory board «Actual problems of glycemic variability as a new criterion of glycemic control and safety of diabetes therapy»https://orcid.org/0000-0002-9944-2997АнциферовМихаил БорисовичAntsiferovMikhail B.

д.м.н., профессор

MD, PhD, Professor

antsiferov@rambler.ruhttps://orcid.org/0000-0001-6581-4521ГалстянГагик РадиковичGalstyanGagik R.

д.м.н., профессор

MD, PhD, Professor

galstyangagik964@gmail.comhttps://orcid.org/0000-0003-3494-8011ЗиловАлексей ВадимовичZilovAlexey V.

к.м.н.

MD, PhD

azilov@hotmail.comhttps://orcid.org/0000-0001-9453-8212МайоровАлександр ЮрьевичMayorovAlexander Y.

д.м.н.

MD, PhD

education@endocrincentr.ruhttps://orcid.org/0000-0002-4882-8494МарковаТатьяна НиколаевнаMarkovaTatyana N.

 д.м.н., профессор

MD, PhD, Professor

markovatn18@yandex.ruhttps://orcid.org/0000-0001-8289-0032ДемидовНиколай АлександровичDemidovNikolay A.

к.м.н.

MD, PhD

nicolay13@mail.ruhttps://orcid.org/0000-0001-8428-4116КотешковаОльга МихайловнаKoteshkovaOlga M.

к.м.н.

MD, PhD

koala58@mail.ruhttps://orcid.org/0000-0002-4316-8546ЛаптевДмитрий НикитичLaptevDmitry N.

д.м.н.

MD, PhD

laptevdn@ya.ruhttps://orcid.org/0000-0001-5689-0194ВитебскаяАлиса ВитальевнаVitebskayaAlisa V.

к.м.н.

к.м.н.

dr.vitebskaya@mail.ru<p>Эндокринологический диспансер Департамента здравоохранения города Москвы</p>Россия<p>Moscow Health Care Department, Endocrinology Dispanserium</p>Russian Federation<p>Национальный медицинский исследовательский центр эндокринологии</p>Россия<p>Endocrinology Research Centre</p>Russian Federation<p>Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)</p>Россия<p>I.M. Sechenov First Moscow State Medical University (Sechenov University)</p>Russian Federation<p>Городская клиническая больница №52; Московский государственный медико-стоматологический университет им. А.И. Евдокимова</p>Россия<p>City Clinical Hospital №52; A.I. Yevdokimov Moscow State University of Medicine and Dentistry</p>Russian Federation<p>Больница г. Московский Департамента здравоохранения города Москвы</p>Россия<p>Moskovskiy City Hospital of Moscow Health Department</p>Russian Federation201920082019223281288Copyright &#x00A9; Анциферов М.Б., Галстян Г.Р., Зилов А.В., Майоров А.Ю., Маркова Т.Н., Демидов Н.А., Котешкова О.М., Лаптев Д.Н., Витебская А.В., 20192019Анциферов М.Б., Галстян Г.Р., Зилов А.В., Майоров А.Ю., Маркова Т.Н., Демидов Н.А., Котешкова О.М., Лаптев Д.Н., Витебская А.В.Antsiferov M.B., Galstyan G.R., Zilov A.V., Mayorov A.Y., Markova T.N., Demidov N.A., Koteshkova O.M., Laptev D.N., Vitebskaya A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/1022719 июня 2018 г

19 июня 2018 г. в Москве состоялось заседание Научно-консультативного совета под председательством д.м.н., профессора Г.Р. Галстяна и к.м.н., доцента А.В. Зилова, посвященное обсуждению возможностей улучшения результатов лечения сахарного диабета (СД) путем использования вариабельности гликемии (ВГ) в качестве дополнительного критерия эффективности контроля гликемии (в первую очередь, на фоне инсулинотерапии), а также одной из целей лечения у пациентов с нестабильной гликемией.

Целью рабочей встречи была выработка стратегии внедрения ВГ в качестве предиктора и дополнительного критерия при оценке эффективности и безопасности сахароснижающей терапии с целью совершенствования фармакотерапии СД и снижения общей и сердечно-сосудистой смертности при этом заболевании.

ЗАДАЧИ

ЗАДАЧИ: провести комплексный анализ данных о взаимосвязи между ВГ и гипогликемией; аккумулировать и проанализировать опубликованные данные и имеющийся опыт снижения ВГ и улучшения исходов СД на фоне различных вариантов инсулинотерапии; сравнить существующие методики мониторинга гликемии и оценки ВГ, их валидность и доступность в реальной практике; проанализировать информативность, клиническую и прогностическую значимость различных параметров оценки ВГ; определить обоснованный «минимум» комплексной оценки ВГ как критерия эффективности лечения СД и предикторов негативных исходов СД.

В рамках дискуссии были заслушаны следующие доклады: «Вариабельность гликемии: Клиническое и прогностическое значение. Виды вариабельности гликемии» (к.м.н., доцент Зилов А.В.); «Методы оценки вариабельности гликемии в клинических исследованиях и рутинной практике» (д.м.н., профессор Маркова Т.Н.); «Действующие международные и национальные рекомендации по мониторингу гликемии» (д.м.н., профессор Галстян Г.Р.); «Особенности вариабельности гликемии и ее оценки у детей и подростков» (к.м.н. Витебская А.В.).

The Scientific Advisory Board, chaired by Professor G. R. Galstyan (cochair - A.V. Zilov), met in Moscow on 19 June 2018 to discuss the possibilities of improving the results of diabetes mellitus (DM) treatment by considering glycaemic variability (GV) as an additional criterion for effective glycaemic control (especially in patients receiving insulin therapy) and as one of the goals of treatment in patients with unstable glycaemia.

The purpose of the working meeting was to develop a strategy for the introduction of GV as a predictor and as an additional criterion for assessing the effectiveness and safety of hypoglycaemic therapy to improve the pharmacotherapy of diabetes and reduce cardiovascular and total mortality.

The aims of the working meeting were to conduct a comprehensive data analysis of the relationship between GV and hypoglycaemia; to gather and analyse published data and the experience of decrease in GV and improved outcomes of diabetes against the background of different types of insulin therapy; to compare existing methods of glycaemia monitoring and GV assessment and examine their validity and availability in real practice in the context of limited budget and to analyse the informativeness and clinical and prognostic significance of various parameters of GV assessment and to determine their reasonable ‘minimum’ for a comprehensive assessment of GV as a criterion for evaluating the effectiveness of DM treatment and the predictors of negative diabetes outcomes.

The following reports were presented during the discussion: ‘Glycemic variability: clinical and prognostic value. Types of glycemic variability’ (Candidate of Medical Sciences, assistant Professor Zilov A.V.); ‘Methods of assessment of variability of glycemia in clinical trials and routine practice’ (PhD, Professor Markova T. N.); ‘Current international and national recommendations on glycemic monitoring’ (PhD, Professor Galstyan G. R.) and ‘Peculiarities of glycemic variability and its evaluation among children and adolescents’ (Candidate of Medical Sciences Vitebskaya A.V.).

вариабельность гликемииHbA1cглюкоза плазмы натощакпостпрандиальная гликемиякоэффициент вариациинепрерывный мониторинг глюкозысамостоятельно измеренная глюкоза кровиинсулин деглудекvariability of glycemiafasting plasma glucosepostprandial glycemiaHbA1ccoefficient of variabilitycontinuous glucose monitoring (CGM)self-measured blood glucosediabetes mellitusinsulin degludecReferencesNalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab. 2010;12(4):288-298. doi: https://doi.org/10.1111/j.1463-1326.2009.01160.xNalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab. 2010;12(4):288-298. doi: https://doi.org/10.1111/j.1463-1326.2009.01160.xHirakawa Y, Arima H, Zoungas S, et al. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care. 2014;37(8):2359-2365. doi: https://doi.org/10.2337/dc14-0199Hirakawa Y, Arima H, Zoungas S, et al. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care. 2014;37(8):2359-2365. doi: https://doi.org/10.2337/dc14-0199Hirsch IB. Glycemic Variability and Diabetes Complications: Does It Matter? Of Course It Does! Diabetes Care. 2015;38(8):1610-1614. doi: https://doi.org/10.2337/dc14-2898Hirsch IB. Glycemic Variability and Diabetes Complications: Does It Matter? Of Course It Does! Diabetes Care. 2015;38(8):1610-1614. doi: https://doi.org/10.2337/dc14-2898Wentholt IM, Kulik W, Michels RP, et al. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia. 2008;51(1):183-190. doi: https://doi.org/10.1007/s00125-007-0842-6Wentholt IM, Kulik W, Michels RP, et al. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia. 2008;51(1):183-190. doi: https://doi.org/10.1007/s00125-007-0842-6Siegelaar SE, Barwari T, Kulik W, et al. No relevant relationship between glucose variability and oxidative stress in well-regulated type 2 diabetes patients. J Diabetes Sci Technol. 2011;5(1):86-92. doi: https://doi.org/10.1177/193229681100500112Siegelaar SE, Barwari T, Kulik W, et al. No relevant relationship between glucose variability and oxidative stress in well-regulated type 2 diabetes patients. J Diabetes Sci Technol. 2011;5(1):86-92. doi: https://doi.org/10.1177/193229681100500112Ohara M, Fukui T, Ouchi M, et al. Relationship between daily and day-to-day glycemic variability and increased oxidative stress in type 2 diabetes. Diabetes Res Clin Pract. 2016;122:62-70. doi: https://doi.org/10.1016/j.diabres.2016.09.025Ohara M, Fukui T, Ouchi M, et al. Relationship between daily and day-to-day glycemic variability and increased oxidative stress in type 2 diabetes. Diabetes Res Clin Pract. 2016;122:62-70. doi: https://doi.org/10.1016/j.diabres.2016.09.025Kohnert KD, Augstein P, Zander E, et al. Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care. 2009;32(6):1058-1062. doi: https://doi.org/10.2337/dc08-1956Kohnert KD, Augstein P, Zander E, et al. Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care. 2009;32(6):1058-1062. doi: https://doi.org/10.2337/dc08-1956Kohnert K-D, Freyse E-J, Salzsieder E. Glycaemic Variability and Pancreatic ß-cell Dysfunction. Curr Diabetes Rev. 2012;8(5):345-354. doi: https://doi.org/10.2174/157339912802083513Kohnert K-D, Freyse E-J, Salzsieder E. Glycaemic Variability and Pancreatic ß-cell Dysfunction. Curr Diabetes Rev. 2012;8(5):345-354. doi: https://doi.org/10.2174/157339912802083513Kim MK, Jung HS, Yoon CS, et al. The Effect of Glucose Fluctuation on Apoptosis and Function of INS-1 Pancreatic Beta Cells. Korean Diabetes J. 2010;34(1):47-54. doi: https://doi.org/10.4093/kdj.2010.34.1.47Kim MK, Jung HS, Yoon CS, et al. The Effect of Glucose Fluctuation on Apoptosis and Function of INS-1 Pancreatic Beta Cells. Korean Diabetes J. 2010;34(1):47-54. doi: https://doi.org/10.4093/kdj.2010.34.1.47Zhang X, Xu X, Jiao X, et al. The effects of glucose fluctuation on the severity of coronary artery disease in type 2 diabetes mellitus. J Diabetes Res. 2013;2013:576916. doi: https://doi.org/10.1155/2013/576916Zhang X, Xu X, Jiao X, et al. The effects of glucose fluctuation on the severity of coronary artery disease in type 2 diabetes mellitus. J Diabetes Res. 2013;2013:576916. doi: https://doi.org/10.1155/2013/576916Muggeo M, Zoppini G, Bonora E, et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care. 2000;23(1):45-50. doi: https://doi.org/10.2337/diacare.23.1.45Muggeo M, Zoppini G, Bonora E, et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care. 2000;23(1):45-50. doi: https://doi.org/10.2337/diacare.23.1.45Lin CC, Li CI, Yang SY, et al. Variation of fasting plasma glucose: a predictor of mortality in patients with type 2 diabetes. Am J Med. 2012;125(4):416 e419-418. doi: https://doi.org/10.1016/j.amjmed.2011.07.027Lin CC, Li CI, Yang SY, et al. Variation of fasting plasma glucose: a predictor of mortality in patients with type 2 diabetes. Am J Med. 2012;125(4):416 e419-418. doi: https://doi.org/10.1016/j.amjmed.2011.07.027Zinman B, Marso SP, Poulter NR, et al. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia. 2018;61(1):48-57. doi: https://doi.org/10.1007/s00125-017-4423-zZinman B, Marso SP, Poulter NR, et al. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia. 2018;61(1):48-57. doi: https://doi.org/10.1007/s00125-017-4423-zKrinsley JS. Glycemic variability: a strong independent predictor of mortality in critically ill patients. Crit Care Med. 2008;36(11):3008-3013. doi: https://doi.org/10.1097/CCM.0b013e31818b38d2Krinsley JS. Glycemic variability: a strong independent predictor of mortality in critically ill patients. Crit Care Med. 2008;36(11):3008-3013. doi: https://doi.org/10.1097/CCM.0b013e31818b38d2DeVries JH. Glucose variability: where it is important and how to measure it. Diabetes. 2013;62(5):1405-1408. doi: https://doi.org/10.2337/db12-1610DeVries JH. Glucose variability: where it is important and how to measure it. Diabetes. 2013;62(5):1405-1408. doi: https://doi.org/10.2337/db12-1610Климонтов В.В., Маякина Н.Е. Вариабельность гликемии при сахарном диабете: инструмент для оценки качества гликемического контроля и риска осложнений // Сахарный диабет. — 2014. — Т. 17. — №2. — С. 76-82. [Klimontov VV, Myakina NE. Glycaemic variability in diabetes: a tool for assessing the quality of glycaemic control and the risk of complications. Diabetes Mellitus. 2014;(2):76-82. (In Russ.)] doi: https://doi.org/10.14341/DM2014276-82Климонтов В.В., Маякина Н.Е. Вариабельность гликемии при сахарном диабете: инструмент для оценки качества гликемического контроля и риска осложнений // Сахарный диабет. — 2014. — Т. 17. — №2. — С. 76-82. [Klimontov VV, Myakina NE. Glycaemic variability in diabetes: a tool for assessing the quality of glycaemic control and the risk of complications. Diabetes Mellitus. 2014;(2):76-82. (In Russ.)] doi: https://doi.org/10.14341/DM2014276-82Bergenstal RM. Glycemic Variability and Diabetes Complications: Does It Matter? Simply Put, There Are Better Glycemic Markers! Diabetes Care. 2015;38(8):1615-1621. doi: https://doi.org/10.2337/dc15-0099Bergenstal RM. Glycemic Variability and Diabetes Complications: Does It Matter? Simply Put, There Are Better Glycemic Markers! Diabetes Care. 2015;38(8):1615-1621. doi: https://doi.org/10.2337/dc15-0099Monnier L, Colette C, Wojtusciszyn A, et al. Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes. Diabetes Care. 2017;40(7):832-838. doi: https://doi.org/10.2337/dc16-1769Monnier L, Colette C, Wojtusciszyn A, et al. Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes. Diabetes Care. 2017;40(7):832-838. doi: https://doi.org/10.2337/dc16-1769Kovatchev BP, Cox DJ, Farhy LS, et al. Episodes of severe hypoglycemia in type 1 diabetes are preceded and followed within 48 hours by measurable disturbances in blood glucose. J Clin Endocrinol Metab. 2000;85(11):4287-4292. doi: https://doi.org/10.1210/jcem.85.11.6999Kovatchev BP, Cox DJ, Farhy LS, et al. Episodes of severe hypoglycemia in type 1 diabetes are preceded and followed within 48 hours by measurable disturbances in blood glucose. J Clin Endocrinol Metab. 2000;85(11):4287-4292. doi: https://doi.org/10.1210/jcem.85.11.6999Patton SR, Clements MA. Average daily risk range as a measure for clinical research and routine care. J Diabetes Sci Technol. 2013;7(5):1370-1375. doi: https://doi.org/10.1177/193229681300700529Patton SR, Clements MA. Average daily risk range as a measure for clinical research and routine care. J Diabetes Sci Technol. 2013;7(5):1370-1375. doi: https://doi.org/10.1177/193229681300700529Ryan EA, Shandro T, Green K, et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes. 2004;53(4):955-962. doi: https://doi.org/10.2337/diabetes.53.4.955Ryan EA, Shandro T, Green K, et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes. 2004;53(4):955-962. doi: https://doi.org/10.2337/diabetes.53.4.955Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH. Glucose variability; does it matter? Endocr Rev. 2010;31(2):171-182. doi: https://doi.org/10.1210/er.2009-0021Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH. Glucose variability; does it matter? Endocr Rev. 2010;31(2):171-182. doi: https://doi.org/10.1210/er.2009-0021Qu Y, Jacober SJ, Zhang Q, et al. Rate of hypoglycemia in insulin-treated patients with type 2 diabetes can be predicted from glycemic variability data. Diabetes Technol Ther. 2012;14(11):1008-1012. doi: https://doi.org/10.1089/dia.2012.0099Qu Y, Jacober SJ, Zhang Q, et al. Rate of hypoglycemia in insulin-treated patients with type 2 diabetes can be predicted from glycemic variability data. Diabetes Technol Ther. 2012;14(11):1008-1012. doi: https://doi.org/10.1089/dia.2012.0099Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681-1687. doi: https://doi.org/10.1001/jama.295.14.1681Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681-1687. doi: https://doi.org/10.1001/jama.295.14.1681Seok H, Huh JH, Kim HM, et al. 1,5-anhydroglucitol as a useful marker for assessing short-term glycemic excursions in type 1 diabetes. Diabetes Metab J. 2015;39(2):164-170. doi: https://doi.org/10.4093/dmj.2015.39.2.164Seok H, Huh JH, Kim HM, et al. 1,5-anhydroglucitol as a useful marker for assessing short-term glycemic excursions in type 1 diabetes. Diabetes Metab J. 2015;39(2):164-170. doi: https://doi.org/10.4093/dmj.2015.39.2.164Bailey TS, Bhargava A, Devries JH, et al. Day-to-day Variability of Fasting Self-Measured Blood Glucose (SMBG) Associates with Hypoglycemia Risk in Adults with Type 1 (T1D) or Type 2 Diabetes (T2D). Can J Diabetes. 2017;41(5):S57. doi: https://doi.org/10.1016/j.jcjd.2017.08.154Bailey TS, Bhargava A, Devries JH, et al. Day-to-day Variability of Fasting Self-Measured Blood Glucose (SMBG) Associates with Hypoglycemia Risk in Adults with Type 1 (T1D) or Type 2 Diabetes (T2D). Can J Diabetes. 2017;41(5):S57. doi: https://doi.org/10.1016/j.jcjd.2017.08.154Bailey T, Bhargava A, Devries JH, et al. Within-day Variability Based on 9-point Profiles Associates with Overall and Nocturnal Hypoglycemia Risk in Adults with Type 1 (T1D) or Type 2 Diabetes (T2D). Can J Diabetes. 2017;41(5):S7. doi: https://doi.org/10.1016/j.jcjd.2017.08.022Bailey T, Bhargava A, Devries JH, et al. Within-day Variability Based on 9-point Profiles Associates with Overall and Nocturnal Hypoglycemia Risk in Adults with Type 1 (T1D) or Type 2 Diabetes (T2D). Can J Diabetes. 2017;41(5):S7. doi: https://doi.org/10.1016/j.jcjd.2017.08.022Vora J, Heise T. Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review. Diabetes Obes Metab. 2013;15(8):701-712. doi: https://doi.org/10.1111/dom.12087Vora J, Heise T. Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review. Diabetes Obes Metab. 2013;15(8):701-712. doi: https://doi.org/10.1111/dom.12087Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14(9):859-864. doi: https://doi.org/10.1111/j.1463-1326.2012.01627.xHeise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14(9):859-864. doi: https://doi.org/10.1111/j.1463-1326.2012.01627.xHeise T, Norskov M, Nosek L, et al. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Diabetes Obes Metab. 2017;19(7):1032-1039. doi: https://doi.org/10.1111/dom.12938Heise T, Norskov M, Nosek L, et al. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Diabetes Obes Metab. 2017;19(7):1032-1039. doi: https://doi.org/10.1111/dom.12938Iga R, Uchino H, Kanazawa K, et al. Glycemic Variability in Type 1 Diabetes Compared with Degludec and Glargine on the Morning Injection: An Open-label Randomized Controlled Trial. Diabetes Ther. 2017;8(4):783-792. doi: https://doi.org/10.1007/s13300-017-0269-0Iga R, Uchino H, Kanazawa K, et al. Glycemic Variability in Type 1 Diabetes Compared with Degludec and Glargine on the Morning Injection: An Open-label Randomized Controlled Trial. Diabetes Ther. 2017;8(4):783-792. doi: https://doi.org/10.1007/s13300-017-0269-0Takahashi H, Nishimura R, Onda Y, et al. Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin detemir using continuous glucose monitoring: a randomized, cross-over, pilot study. Expert Opin Pharmacother. 2017;18(4):335-342. doi: https://doi.org/10.1080/14656566.2017.1293652Takahashi H, Nishimura R, Onda Y, et al. Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin detemir using continuous glucose monitoring: a randomized, cross-over, pilot study. Expert Opin Pharmacother. 2017;18(4):335-342. doi: https://doi.org/10.1080/14656566.2017.1293652Henao-Carrillo DC, Munoz OM, Gomez AM, et al. Reduction of glycemic variability with Degludec insulin in patients with unstable diabetes. J Clin Transl Endocrinol. 2018;12:8-12. doi: https://doi.org/10.1016/j.jcte.2018.03.003Henao-Carrillo DC, Munoz OM, Gomez AM, et al. Reduction of glycemic variability with Degludec insulin in patients with unstable diabetes. J Clin Transl Endocrinol. 2018;12:8-12. doi: https://doi.org/10.1016/j.jcte.2018.03.003Marso SP, McGuire DK, Zinman B, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017;377(8):723-732. doi: https://doi.org/10.1056/NEJMoa1615692Marso SP, McGuire DK, Zinman B, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017;377(8):723-732. doi: https://doi.org/10.1056/NEJMoa1615692Danne T, Nimri R, Battelino T, et al. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017;40(12):1631-1640. doi: https://doi.org/10.2337/dc17-1600Danne T, Nimri R, Battelino T, et al. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017;40(12):1631-1640. doi: https://doi.org/10.2337/dc17-1600Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther. 2013;15(3):198-211. doi: https://doi.org/10.1089/dia.2013.0051Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther. 2013;15(3):198-211. doi: https://doi.org/10.1089/dia.2013.0051Su G, Mi S, Tao H, et al. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2011;10:19. doi: https://doi.org/10.1186/1475-2840-10-19Su G, Mi S, Tao H, et al. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2011;10:19. doi: https://doi.org/10.1186/1475-2840-10-19

The authors declare that there are no conflicts of interest present.